

# Luca V Cappelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1480614/publications.pdf>

Version: 2024-02-01

17  
papers

360  
citations

933447

10  
h-index

996975

15  
g-index

19  
all docs

19  
docs citations

19  
times ranked

707  
citing authors

#	ARTICLE	IF	CITATIONS
1	Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration. <i>Leukemia</i> , 2022, 36, 394-402.	7.2	24
2	Treatment with ibrutinib does not induce a <math>TP53</math> clonal evolution in chronic lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 334-337.	3.5	4
3	Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 893-900.	2.8	7
4	In Vivo and Ex Vivo Patient-Derived Tumor Xenograft Models of Lymphoma for Drug Discovery. <i>Current Protocols</i> , 2021, 1, e96.	2.9	1
5	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 637186.	2.8	17
6	PKC $\beta$ inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. <i>Molecular Cell</i> , 2021, 81, 4509-4526.e10.	9.7	12
7	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. <i>Life Science Alliance</i> , 2021, 4, e202000955.	2.8	56
8	Selective STAT3 Degradation Dissects Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens. <i>Blood</i> , 2021, 138, 865-865.	1.4	0
9	A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments. <i>Blood</i> , 2021, 138, 704-704.	1.4	0
10	Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 809937.	4.8	13
11	Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy. <i>British Journal of Haematology</i> , 2020, 188, 249-258.	2.5	16
12	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020, 12, 1603.	3.7	11
13	Peripheral T cell lymphomas: from the bench to the clinic. <i>Nature Reviews Cancer</i> , 2020, 20, 323-342.	28.4	74
14	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. <i>British Journal of Haematology</i> , 2020, 189, 853-859.	2.5	18
15	Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?. <i>Frontiers in Oncology</i> , 2019, 9, 689.	2.8	41
16	DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern. <i>Leukemia</i> , 2019, 33, 2741-2746.	7.2	15
17	Comparative analysis between <math>RQ</math> and digital droplet <math>PCR</math> of <math>BCL2</math> <math>IGH</math> gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 177, 588-596.	2.5	39